Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus
- First Posted Date
- 2011-07-08
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- Amgen
- Target Recruit Count
- 1
- Registration Number
- NCT01389895
- Locations
- 🇨🇦
Research Site, Peterborough, Ontario, Canada
Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid Tumors
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2011-07-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 4
- Registration Number
- NCT01386866
LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy
Phase 2
Completed
- Conditions
- Hyperlipidemia
- Interventions
- Other: Placebo to EvolocumabBiological: Evolocumab
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 631
- Registration Number
- NCT01380730
- Locations
- 🇭🇺
Research Site, Zalaegerszeg, Hungary
Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia
Phase 1
Completed
- Conditions
- CancerHematologic MalignanciesMyeloid LeukemiaLeukemia
- Interventions
- Drug: Arm 1- Dose EscalationDrug: Arm 2- Dose Expansion
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 35
- Registration Number
- NCT01380756
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
Phase 2
Completed
- Conditions
- Hyperlipidemia
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 411
- Registration Number
- NCT01375777
- Locations
- 🇩🇰
Research Site, Vejle, Denmark
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
Phase 2
Completed
- Conditions
- Hyperlipidemia
- Interventions
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 160
- Registration Number
- NCT01375764
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
Phase 2
Completed
- Conditions
- Hypercholesterolemia, Familial
- Interventions
- Biological: PlaceboBiological: Evolocumab
- First Posted Date
- 2011-06-17
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 168
- Registration Number
- NCT01375751
A Study to Evaluate the Safety and Efficacy of CCX168 in Subjects With ANCA-Associated Vasculitis
- First Posted Date
- 2011-06-01
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 67
- Registration Number
- NCT01363388
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 147
- Registration Number
- NCT01362140
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs)
- First Posted Date
- 2011-05-04
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 23
- Registration Number
- NCT01347073
- Locations
- 🇺🇸
UCLA Pediatrics/Genetics, Los Angeles, California, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath